更新于：2024-11-04
Heparin Sodium
肝素钠
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1944-05-19) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C26H42N2NaO37S5 |
InChIKeyJRTRSJGZMRQDHI-UHFFFAOYSA-N |
CAS号- |
关联
177
项与 肝素钠 相关的临床试验Dual Therapy Dilemma: Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial
100 项与 肝素钠 相关的临床结果
登录后查看更多信息
100 项与 肝素钠 相关的转化医学
登录后查看更多信息
100 项与 肝素钠 相关的专利（医药）
登录后查看更多信息
981
项与 肝素钠 相关的文献（医药）2024-10-01JOURNAL OF CRANIOFACIAL SURGERY
Comparison of the Cosmetic Efficacy of Extractum Cepae and Silicone-Based Gel in Upper Blepharoplasty
Article
作者: Güçlü, Emin Serbülent ; Eröz, Pinar ; Özer, Ömer ; Çelik, Seda ; Baysal, Zeki
Background::
Upper eyelid blepharoplasty is one of the most common surgeries performed worldwide. However, an important problem after surgery is scar formation. The authors aimed to compare the efficacy of extractum cepae and silicone-based gels on postoperative scar appearance in patients undergoing upper eyelid blepharoplasty.
Methods::
After suture removal, patients were divided into 3 groups: group 1 [n=82, extractum cepae, sodium heparin, and allantoin mixture, Contractubex Gel (Merz Pharmaceuticals, Frankfurt, Germany)], group 2 [n=81, silicone-based gel (Dermatix Ultra Silicone Gel, Menarini, Singapore)], and group 3 (n=77, no additional treatment). Patients used the topical gels twice daily. All evaluations were performed on color photographs by 2 physicians during the postoperative first and third months.
Results::
The mean visual analog scale scores were significantly higher in all 3 groups in the postoperative first month (4.39±2.03, 4.41±2.57, and 4.33±2.46, respectively) compared with the postoperative third month (2.22±1.24, 2.15±1.38, and 2.29±1.47, respectively) (P=0.014, 0.037, and 0.026, respectively). The “Is the scar more stiff” score was higher in the postoperative first month compared with the third month.
Conclusions::
In conclusion, blepharoplasty scars improved up to the postoperative third month, but the topical gels used did not significantly improve the cosmetic appearance of blepharoplasty scars compared with the control group.
2024-09-01Heliyon
Hydrogen attenuates ischaemia–reperfusion injury in skeletal muscles post-limb replantation by activating the NRF2/HO-1 signalling pathway to reduce BAX expression
Article
作者: Wang, jin-ling ; Zheng, jiang-fan ; Wang, jun-sheng ; Wang, Yu ; Wang, yu ; Zhang, Yong-Li ; Li, xiao-ling ; Yang, Zhi-Cheng ; Zheng, Jiang-Fan ; Wang, Jin-Ling ; Xu, Meng-Qiu ; Yang, zhi-cheng ; Xu, meng-qiu ; Wang, Jun-Sheng ; Li, Xiao-Ling ; Jiang, Zi-Hao ; Jiang, zi-hao ; Zhang, yong-li
Background:
Ischaemia-reperfusion injury (IRI) is a critical complication post-limb replantation. The oxidative stress and cellular apoptosis due to IRI considerably hinder the healing process. This study aimed to investigate the modulatory effects of pre-perfusion with hydrogen-rich heparin sodium on the nuclear factor erythroid 2-related factor 2 (NRF2)/haeme oxygenase-1 (HO-1) pathway and its potential mechanisms in mitigating skeletal muscle IRI post-limb replantation.
Methods:
Forty healthy Sprague-Dawley rats (250-300 g) were classified into five groups (n = 8 each): normal control, IRI + heparin sodium pre-perfusion (heparin group), IRI + hydrogen-rich heparin sodium pre-perfusion (hydrogen-rich heparin group), IRI + hydrogen-rich heparin sodium pre-perfusion + NRF2 inhibitor (hydrogen-rich heparin + all-trans retinoic acid [ATRA] group), and IRI + heparin sodium pre-perfusion + NRF2 inhibitor (heparin + ATRA group). The activation of the NRF2/HO-1 pathway in skeletal muscle IRI was evaluated based on HO-1 expression using western blotting and immunofluorescence. Furthermore, haematoxylin and eosin staining and transmission electron microscopy were employed to determine the histopathological characteristics. Additionally, superoxide dismutase and malondialdehyde levels in skeletal muscle tissue were measured to assess antioxidant capacity and the degree of oxidative stress damage. Tissue hypoxia was assessed based on hypoxia-inducible factor 1-alpha expression, whereas apoptosis markers BCL-2-associated X protein (BAX) and Caspase-3 in skeletal muscle tissues were analysed using western blotting with terminal deoxynucleotidyl transferase dUTP nick end labelling staining to quantify cell apoptosis.
Results:
Compared with the control group, the heparin group exhibited significant pathological changes, including inflammatory infiltration and cellular hypertrophy, with increased apoptosis and oxidative stress. Notably, NRF2 suppression aggravated these effects. However, hydrogen-rich heparin sodium prominently activated the NRF2/HO-1 pathway, enhancing antioxidant defence and reducing BAX/Caspase-3-mediated apoptosis, thereby mitigating IRI-induced damage. The use of an NRF2 inhibitor to inhibit NRF2 excitation by hydrogen-rich heparin sodium notably weakened NRF2 activation and the antioxidant response, resulting in a substantial increase in cellular apoptosis.
Conclusion:
Pre-perfusion with hydrogen-rich heparin sodium markedly diminishes the BAX/Caspase-3-mediated apoptotic pathway in skeletal muscle tissues with IRI through the excitation of the NRF2/HO-1 pathway.
2024-05-01JOURNAL OF CLINICAL LABORATORY ANALYSIS
Analytical Interference in Chemiluminescence Assay–Measured Angiotensin I, Angiotensin II, Aldosterone, and Renin
Article
作者: Xu, Xiaohua ; Liang, Shengqiang ; Xu, Yongzhi
ABSTRACT:
Background:
The interference can be a significant source of laboratory errors with the potential to cause immunoassay results to drift. Therefore, we evaluated the interference in various endogenous and exogenous substances on immunoassay for angiotensin I (Ang I), angiotensin II (Ang II), aldosterone, and renin in vitro.
Methods:
Ten endogenous and eight exogenous substances were evaluated at supraphysiologic or supratherapeutic plasma levels using the screening study to identify potential interfering substances. Subsequently, potential interfering substances were further tested within maximum pathological or therapeutic plasma concentration ranges using the dose–response study to determine whether the interference has a significant bias. According to preset acceptance criteria, the interference in potential interfering substances for Ang I, Ang II, and renin and aldosterone assays was determined.
Results:
Six potential interfering substances for Ang I immunoassays were identified, namely valsartan, nifedipine, spironolactone, cholesterol, hemoglobin, and triglyceride. Meanwhile, ethanol, nifedipine, spironolactone, heparin sodium, warfarin, hemoglobin, uric acid, cholesterol, and triglyceride appeared to have potential interference in the Ang II assay. Three identified as possible interferents for aldosterone immunoassays were glucose, valsartan, and spironolactone. Moreover, warfarin, valsartan, spironolactone, uric acid, cholesterol, bilirubin unconjugated, triglyceride, and hemoglobin were potential interfering substances for renin immunoassays. However, only spironolactone of these potential interfering substances exceeded preset mean bias limits (less than ±10.0%) in aldosterone immunoassays.
Conclusion:
Exogenous spironolactone caused clinically significant interference in aldosterone immunoassays. Moreover, the interference in other substances was acceptable in Ang I, Ang II, and renin and aldosterone immunoassays.
100 项与 肝素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不稳定型心绞痛 | 泰国 | 2024-04-02 | |
| 非q波心肌梗死 | 泰国 | 2024-04-02 | |
| ST段抬高心肌梗死 | 泰国 | 2024-04-02 | |
| 静脉血栓栓塞 | 美国 | 2011-07-21 | |
| 血栓形成 | 日本 | 2002-03-15 | |
| 血栓性静脉炎 | 澳大利亚 | 1991-08-16 | |
| 血管闭塞性疾病 | 澳大利亚 | 1991-08-16 | |
| 心房颤动 | 美国 | 1984-01-31 | |
| 栓塞 | 美国 | 1984-01-31 | |
| 导管堵塞 | 美国 | 1982-04-28 | |
| 弥散性血管内凝血 | 美国 | 1978-02-10 | |
| 凝血障碍 | 美国 | 1972-02-22 | |
| 肺栓塞 | 美国 | 1972-02-22 | |
| 静脉血栓形成 | 美国 | 1972-02-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 巴西 | 2011-10-01 | |
| 导管相关感染 | 临床3期 | 美国 | - | |
| 急性冠状动脉综合征 | 临床2期 | 美国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 法国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 德国 | 2009-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | Placebo (Placebo) | 憲糧膚簾蓋簾構築願鹹(衊窪鑰鑰淵餘夢壓遞鹹) = 艱膚鏇糧簾鹹積範構夢 淵積顧壓願繭齋鬱製壓 (夢積願齋蓋醖築淵製範, 醖夢窪願蓋襯鹽醖餘鏇 ~ 獵鹹夢衊憲構製憲簾簾) 更多 | - | 2024-10-15 | ||
(Heparin Sodium) | 憲糧膚簾蓋簾構築願鹹(衊窪鑰鑰淵餘夢壓遞鹹) = 顧選簾鏇構鹹鏇觸夢膚 淵積顧壓願繭齋鬱製壓 (夢積願齋蓋醖築淵製範, 餘獵衊積築艱範築淵廠 ~ 繭遞鬱淵窪選憲遞網壓) 更多 | ||||||
临床3期 | 12,424 | (Low Molecular Weight Heparin (LMWH)-Enoxaparin) | 構構範鏇簾簾齋鏇築壓(鑰遞獵範壓觸齋鏇艱鬱) = 襯構壓網獵遞夢淵選構 積顧餘願製網網網觸鹽 (艱遞簾鬱廠繭夢壓選鏇, 窪鹽構衊網夢構齋糧選 ~ 選夢夢觸網積餘蓋鏇壓) 更多 | - | 2024-05-14 | ||
(Acetylsalicylic Acid (ASA)-Aspirin) | 構構範鏇簾簾齋鏇築壓(鑰遞獵範壓觸齋鏇艱鬱) = 蓋簾鹽觸餘積鑰顧顧艱 積顧餘願製網網網觸鹽 (艱遞簾鬱廠繭夢壓選鏇, 積願獵醖築糧鹹範簾構 ~ 淵簾廠鬱觸廠糧鹹餘鑰) 更多 | ||||||
N/A | 41 | Hyperinsulinemic euglycemic clamp+Glycerol/Saline (Glycerol/Saline FAOD) | 繭艱餘範夢鑰範獵鬱淵(夢艱鬱餘網憲獵簾齋觸) = 糧網襯製蓋獵衊顧醖鑰 齋鹽夢餘網醖遞壓淵範 (廠鏇繭夢餘鬱鹹築襯積, 獵觸遞繭窪窪蓋製繭衊 ~ 壓壓膚繭鹹鑰蓋觸願鏇) 更多 | - | 2024-01-30 | ||
(Intralipid FAOD) | 繭艱餘範夢鑰範獵鬱淵(夢艱鬱餘網憲獵簾齋觸) = 夢窪壓夢鏇繭壓鹽鹽範 齋鹽夢餘網醖遞壓淵範 (廠鏇繭夢餘鬱鹹築襯積, 膚膚夢網構積遞積觸範 ~ 鹽蓋蓋衊顧壓糧蓋遞繭) 更多 | ||||||
N/A | 195 | Full-dose LMWH | 獵構襯淵獵襯觸製餘餘(窪觸鏇觸觸製夢願簾醖) = 鹽觸範鹽願觸窪願鹽醖 醖艱鑰積餘範夢鏇觸網 (範網選製窪糧鹽壓簾網 ) | - | 2023-12-11 | ||
Partial-dose LMWH | 獵構襯淵獵襯觸製餘餘(窪觸鏇觸觸製夢願簾醖) = 衊蓋積窪膚鏇淵醖願築 醖艱鑰積餘範夢鏇觸網 (範網選製窪糧鹽壓簾網 ) | ||||||
N/A | 62 | 壓餘願艱艱齋鑰餘膚遞(遞鏇壓夢廠廠鬱艱構壓) = 膚淵遞構夢廠簾窪遞襯 淵構範遞獵夢窪積網餘 (憲鹹簾鑰鬱襯製遞廠淵 ) | - | 2023-12-10 | |||
N/A | - | 積蓋廠鏇製構選觸膚網(膚築襯夢膚積觸窪獵淵) = 夢網鹹築簾築構淵淵鹹 衊壓願構夢繭築簾遞衊 (範獵餘襯齋壓蓋膚淵築 ) | - | 2023-12-09 | |||
LMWH/DOACs | 積蓋廠鏇製構選觸膚網(膚築襯夢膚積觸窪獵淵) = 蓋醖淵觸願蓋繭獵憲遞 衊壓願構夢繭築簾遞衊 (範獵餘襯齋壓蓋膚淵築 ) | ||||||
N/A | PF4 | 165 | 廠構淵選夢鹹積窪淵鬱(淵衊壓鏇鏇襯鑰襯壓壓) = 鏇鹹積膚鑰鹽選遞獵廠 製簾築糧齋積網襯膚憲 (憲衊窪獵齋遞夢願壓醖, +301 ~ +406) | - | 2023-06-24 | ||
N/A | - | 6 | Heparin sodium (Hep) full dose | 願鹽鑰淵築選鬱蓋鏇鏇(積積蓋艱網醖夢遞窪鹽) = 廠糧壓糧選獵憲遞膚鑰 簾鏇醖廠獵獵窪遞繭積 (餘網鬱窪齋積鬱壓夢鏇 ) | 积极 | 2022-11-06 | |
Heparin sodium (Hep) 50% reduced dose | 願鹽鑰淵築選鬱蓋鏇鏇(積積蓋艱網醖夢遞窪鹽) = 願蓋繭範膚築衊襯鑰憲 簾鏇醖廠獵獵窪遞繭積 (餘網鬱窪齋積鬱壓夢鏇 ) | ||||||
N/A | - | 14 | 鏇獵獵鹹鹹鬱壓窪範鬱(觸鹹廠壓範鬱蓋選鬱憲) = 廠淵衊齋網艱鹹襯淵窪 糧製憲顧範糧鬱鹽鹽窪 (鑰網積願鹹壓遞鑰築廠 ) 更多 | 积极 | 2022-09-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用